Puretech Health PLC

PureTech Health discloses the automatic conversion of preferred stock holdings into common stock following Seaport Therapeutics' IPO.

PureTech Health plc disposed of its Akili, Inc. shares at $0.4340 per share following the completion of a merger with Virtual Therapeutics Corporation on July 2, 2024.

Citigroup Inc. and its subsidiaries have reported beneficial ownership of 14,636,273 ordinary shares, representing 6.0% of PureTech Health plc.

Tang Capital Management, LLC and affiliated entities have reported beneficial ownership of 5.19% of PureTech Health plc's ordinary shares.

Citigroup and its affiliates have disclosed a 5.5% beneficial ownership stake in Puretech Health Plc, holding over 13.2 million ordinary shares.

Citigroup Global Markets Limited and affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 4.5% of Puretech Health Plc's Ordinary Shares as of December 31, 2024.